Transformative Therapeutics

NGM Bio is a clinical-stage biopharmaceutical company committed to developing first-in-class biologic therapeutics, with an initial focus on cardio-metabolic disease, liver disease and immuno-oncology. Our in-depth biology-based approach to drug discovery is designed to identify therapeutics that address the fundamental mechanisms underlying disease states. We are seeking to develop products that significantly improve upon existing treatments. Our goal is to generate transformative therapeutics that will profoundly improve patients’ lives.

NASH1
Phase 2
     
NASH1, Diabetes
Phase 1b
     
Obesity
Phase 1
     
Obesity
Preclinical
     
Cancer Anorexia/Cachexia Syndrome
Phase 1
     
Diabetes
Phase 1
     
AMD
Preclinical
     
Drug Candidate
Indication
Status

1 non-alcoholic steatohepatitis